S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
P-415: Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the life study
Henrik M. Reims,Sverre E. Kjeldsen,Richard B. Devereux,Suzanne Oparil,Stevo Julius,William E. Brady,Björn Dahlöf +6 more
TL;DR: The benefit of losartan vs atenolol is consistent with the overall conclusion of the LIFE study, although the treatment effect appeared largest in non-smokers, and a borderline significant trend suggested decreasing benefit ofLosartan Vs atanolol for stroke prevention from never- to previous to current smoking status.
Journal ArticleDOI
Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence.
Sverre E. Kjeldsen,Fadl Elmula M. Fadl Elmula,Ingrid Os,Alexandre Persu,Yu Jin,Jan A. Staessen,Jan A. Staessen +6 more
TL;DR: The overall BP lowering effect of RDN seems rather limited and the characteristics of the true responders remain largely unknown, Accordingly, RDN is not ready for clinical practice.
Journal ArticleDOI
Increased erythrocyte magnesium in never treated essential hypertension.
TL;DR: Investigation of the intracellular concentrations of magnesium, potassium and sodium in 50-year-old, otherwise healthy white men with never treated, essential hypertension and in normotensive control subjects found increased intrACEllular magnesium probably unrelated to intrace cellular potassium-sodium imbalance in never treated and essential hypertension.
Journal ArticleDOI
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Maria H Mehlum,Maria H Mehlum,Knut Liestøl,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Torgeir Bruun Wyller,Torgeir Bruun Wyller,Stevo Julius,Peter M. Rothwell,Giuseppe Mancia,Gianfranco Parati,Michael A. Weber,Eivind Berge +13 more
TL;DR: The higher risks of myocardial infarction and stroke in patients randomized to valsartan versus amlodipine were related to the drugs’ different blood pressure modulating profiles, and the risk of congestive heart failure with vALSartan was lower, independent of the less favorable blood Pressure modulating profile.
Journal ArticleDOI
Adrenaline and Preeclampsia
TL;DR: For instance, this article found that preeclamptic women had increased venous plasma-free adrenaline (45 +/- 5 vs 27 +/- 2 pg/ml, mean +/- SE, P less than 0.01) compared with fifteen normotensive pregnant women, supporting increased sympathetic nervous tone in the development of preeclampsia.